

Receipt date: 07/14/2006

10574098 - GAU: 1625

MODIFIED PTO/SB/08 A & B (08-03)

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/574,098
Confirmation Number	Unknown
Filing Date	March 31, 2006
First Named Inventor	Keuk Chan BANG
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q94052

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		KR	10-580743	B1	05/09/2006	Hanmi Pharm. Co., Ltd.	Abstract
		WO	94/01408	A1	01/20/1994	Laboratoires Glaxo	
		WO	98/17648	A1	04/30/1998	Xenova Limited	
		WO	03/095447	A1	11/20/2003	Xenova Limited	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		M. Roe et al., "Reversal of P-Glycoprotein Media Multidrug Resistance by Novel Anthranilamide Derivatives", Bioorganic & Medicinal Chemistry Letters 9, (4), 1999, pp. 595-600.	
		P. Mistry et al., "In Vitro and in Vivo Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576", Cancer Research, 61 (2), January 15, 2001.	
		A. Stewart et al., "Phase I Trial of XR9576 in Healthy Volunteers Demonstrates Modulation of P-Glycoprotein in CD56 ⁺ Lymphocytes after Oral and Intravenous Administration", Clinical Cancer Research, Vol. 6, November 2000, pp. 4186-4191.	

Examiner Signature

/Zinna Davis/ (01/14/2009)

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZD/